checkAd

    EQS-Adhoc  105  0 Kommentare APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications

    Für Sie zusammengefasst
    • APONTIS PHARMA raises forecast
    • Five-year agreement with Novartis
    • Sales increase to EUR 50.7 million

    EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Forecast/Change in Forecast
    APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications

    05-Apr-2024 / 10:10 CET/CEST
    Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014

    APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications

    Monheim / Rhein, 5 April 2024. APONTIS PHARMA AG (“APONTIS PHARMA” or the “Company”, Ticker APPH / ISIN DE000A3CMGM5) has entered into a five-year agreement with Novartis Pharma GmbH to take over the distribution and marketing of two medications in the asthma indication for Germany. The Company expects a sales contribution of around EUR 9 million and an earnings contribution of up to EUR 1.5 million for the 2024 financial year. APONTIS PHARMA is therefore raising its forecast for 2024 and now expects an increase in sales to EUR 50.7 million (previously: EUR 41.7 million) and a positive EBITDA of EUR 3.3 million (previously: positive EBITDA of EUR 1.8 million).

    APONTIS PHARMA AG

    Investor Relations
    ir@apontis-pharma.de
    T: +49 2173 89 55 4900
    F: +49 2173 89 55 1521
    Alfred-Nobel-Str. 10
    40789 Monheim / Rhein
    Germany
    apontis-pharma.de

    APONTIS PHARMA press contact

    CROSS ALLIANCE communication GmbH
    Sven Pauly
    ir@apontis-pharma.de
    T: +49 89 125 09 0330



    End of Inside Information

    05-Apr-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.eqs-news.com

    Language: English
    Company: APONTIS PHARMA AG
    Alfred-Nobel-Str. 10
    40789 Monheim
    Germany
    E-mail: ir@apontis-pharma.de
    Internet: https://apontis-pharma.de/
    ISIN: DE000A3CMGM5
    WKN: A3CMGM
    Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange
    EQS News ID: 1873383

     
    End of Announcement EQS News Service

    1873383  05-Apr-2024 CET/CEST

    fncls.ssp?fn=show_t_gif&application_id=1873383&application_name=news&site_id=wallstreet~~~257e03b8-9cbc-48b8-b6a5-ec526abf7b8e 

    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    EQS-Adhoc APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Forecast/Change in Forecast APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications 05-Apr-2024 / 10:10 CET/CEST …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer